|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PPP1CC |
Gene summary for PPP1CC |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PPP1CC | Gene ID | 5501 |
| Gene name | protein phosphatase 1 catalytic subunit gamma | |
| Gene Alias | PP-1G | |
| Cytomap | 12q24.11 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | P36873 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5501 | PPP1CC | HTA11_78_2000001011 | Human | Colorectum | AD | 2.00e-04 | 4.19e-01 | -0.1088 |
| 5501 | PPP1CC | HTA11_347_2000001011 | Human | Colorectum | AD | 2.70e-05 | 3.16e-01 | -0.1954 |
| 5501 | PPP1CC | HTA11_99999970781_79442 | Human | Colorectum | MSS | 7.26e-09 | 5.35e-01 | 0.294 |
| 5501 | PPP1CC | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 3.62e-03 | 1.10e+00 | 0.3487 |
| 5501 | PPP1CC | A015-C-203 | Human | Colorectum | FAP | 2.96e-06 | -2.23e-01 | -0.1294 |
| 5501 | PPP1CC | A001-C-108 | Human | Colorectum | FAP | 2.81e-05 | -2.32e-01 | -0.0272 |
| 5501 | PPP1CC | A002-C-205 | Human | Colorectum | FAP | 2.07e-03 | -2.21e-01 | -0.1236 |
| 5501 | PPP1CC | A015-C-106 | Human | Colorectum | FAP | 2.40e-03 | -1.69e-01 | -0.0511 |
| 5501 | PPP1CC | A015-C-104 | Human | Colorectum | FAP | 2.71e-06 | -2.38e-01 | -0.1899 |
| 5501 | PPP1CC | A001-C-014 | Human | Colorectum | FAP | 5.58e-04 | -2.01e-01 | 0.0135 |
| 5501 | PPP1CC | A002-C-016 | Human | Colorectum | FAP | 9.31e-07 | -1.45e-01 | 0.0521 |
| 5501 | PPP1CC | A001-C-203 | Human | Colorectum | FAP | 1.12e-02 | -1.76e-01 | -0.0481 |
| 5501 | PPP1CC | A002-C-116 | Human | Colorectum | FAP | 1.03e-08 | -1.92e-01 | -0.0452 |
| 5501 | PPP1CC | A018-E-020 | Human | Colorectum | FAP | 1.05e-02 | -2.27e-01 | -0.2034 |
| 5501 | PPP1CC | LZE2D | Human | Esophagus | HGIN | 1.06e-06 | 1.48e-01 | 0.0642 |
| 5501 | PPP1CC | LZE4T | Human | Esophagus | ESCC | 2.75e-12 | 5.12e-01 | 0.0811 |
| 5501 | PPP1CC | LZE5T | Human | Esophagus | ESCC | 1.32e-02 | -1.08e-01 | 0.0514 |
| 5501 | PPP1CC | LZE7T | Human | Esophagus | ESCC | 1.84e-06 | 9.47e-01 | 0.0667 |
| 5501 | PPP1CC | LZE8T | Human | Esophagus | ESCC | 1.82e-02 | 8.32e-02 | 0.067 |
| 5501 | PPP1CC | LZE20T | Human | Esophagus | ESCC | 8.39e-04 | 2.62e-01 | 0.0662 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006091 | Colorectum | AD | generation of precursor metabolites and energy | 209/3918 | 490/18723 | 3.17e-28 | 6.61e-25 | 209 |
| GO:0015980 | Colorectum | AD | energy derivation by oxidation of organic compounds | 143/3918 | 318/18723 | 2.78e-22 | 2.49e-19 | 143 |
| GO:0006913 | Colorectum | AD | nucleocytoplasmic transport | 102/3918 | 301/18723 | 1.00e-07 | 4.85e-06 | 102 |
| GO:0051169 | Colorectum | AD | nuclear transport | 102/3918 | 301/18723 | 1.00e-07 | 4.85e-06 | 102 |
| GO:0032386 | Colorectum | AD | regulation of intracellular transport | 109/3918 | 337/18723 | 5.33e-07 | 1.95e-05 | 109 |
| GO:0007623 | Colorectum | AD | circadian rhythm | 72/3918 | 210/18723 | 4.50e-06 | 1.21e-04 | 72 |
| GO:0048511 | Colorectum | AD | rhythmic process | 94/3918 | 298/18723 | 1.00e-05 | 2.34e-04 | 94 |
| GO:0016311 | Colorectum | AD | dephosphorylation | 123/3918 | 417/18723 | 1.84e-05 | 3.82e-04 | 123 |
| GO:0046822 | Colorectum | AD | regulation of nucleocytoplasmic transport | 41/3918 | 106/18723 | 2.17e-05 | 4.33e-04 | 41 |
| GO:0006470 | Colorectum | AD | protein dephosphorylation | 88/3918 | 281/18723 | 2.56e-05 | 4.89e-04 | 88 |
| GO:0044262 | Colorectum | AD | cellular carbohydrate metabolic process | 87/3918 | 283/18723 | 6.00e-05 | 1.01e-03 | 87 |
| GO:0010720 | Colorectum | AD | positive regulation of cell development | 87/3918 | 298/18723 | 4.17e-04 | 4.71e-03 | 87 |
| GO:0042752 | Colorectum | AD | regulation of circadian rhythm | 40/3918 | 121/18723 | 1.24e-03 | 1.09e-02 | 40 |
| GO:0050767 | Colorectum | AD | regulation of neurogenesis | 99/3918 | 364/18723 | 2.35e-03 | 1.82e-02 | 99 |
| GO:00060912 | Colorectum | MSS | generation of precursor metabolites and energy | 186/3467 | 490/18723 | 1.14e-24 | 2.15e-21 | 186 |
| GO:00159802 | Colorectum | MSS | energy derivation by oxidation of organic compounds | 131/3467 | 318/18723 | 2.60e-21 | 2.70e-18 | 131 |
| GO:00069132 | Colorectum | MSS | nucleocytoplasmic transport | 99/3467 | 301/18723 | 1.35e-09 | 1.03e-07 | 99 |
| GO:00511692 | Colorectum | MSS | nuclear transport | 99/3467 | 301/18723 | 1.35e-09 | 1.03e-07 | 99 |
| GO:00323862 | Colorectum | MSS | regulation of intracellular transport | 102/3467 | 337/18723 | 9.73e-08 | 4.71e-06 | 102 |
| GO:00076232 | Colorectum | MSS | circadian rhythm | 69/3467 | 210/18723 | 4.22e-07 | 1.67e-05 | 69 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04218110 | Oral cavity | OSCC | Cellular senescence | 112/3704 | 156/8465 | 8.04e-13 | 1.42e-11 | 7.21e-12 | 112 |
| hsa0301513 | Oral cavity | OSCC | mRNA surveillance pathway | 75/3704 | 97/8465 | 1.30e-11 | 2.01e-10 | 1.02e-10 | 75 |
| hsa05415113 | Oral cavity | OSCC | Diabetic cardiomyopathy | 131/3704 | 203/8465 | 1.33e-09 | 1.49e-08 | 7.57e-09 | 131 |
| hsa04510110 | Oral cavity | OSCC | Focal adhesion | 128/3704 | 203/8465 | 1.71e-08 | 1.63e-07 | 8.31e-08 | 128 |
| hsa05205111 | Oral cavity | OSCC | Proteoglycans in cancer | 128/3704 | 205/8465 | 4.00e-08 | 3.12e-07 | 1.59e-07 | 128 |
| hsa0491013 | Oral cavity | OSCC | Insulin signaling pathway | 83/3704 | 137/8465 | 4.83e-05 | 2.00e-04 | 1.02e-04 | 83 |
| hsa04810111 | Oral cavity | OSCC | Regulation of actin cytoskeleton | 129/3704 | 229/8465 | 7.14e-05 | 2.74e-04 | 1.40e-04 | 129 |
| hsa041141 | Oral cavity | OSCC | Oocyte meiosis | 74/3704 | 131/8465 | 2.13e-03 | 5.75e-03 | 2.92e-03 | 74 |
| hsa0439017 | Oral cavity | OSCC | Hippo signaling pathway | 86/3704 | 157/8465 | 3.30e-03 | 8.24e-03 | 4.20e-03 | 86 |
| hsa0493112 | Oral cavity | OSCC | Insulin resistance | 60/3704 | 108/8465 | 8.66e-03 | 1.97e-02 | 1.00e-02 | 60 |
| hsa05415210 | Oral cavity | LP | Diabetic cardiomyopathy | 106/2418 | 203/8465 | 6.51e-13 | 1.36e-11 | 8.74e-12 | 106 |
| hsa0301523 | Oral cavity | LP | mRNA surveillance pathway | 50/2418 | 97/8465 | 1.39e-06 | 1.50e-05 | 9.66e-06 | 50 |
| hsa0421827 | Oral cavity | LP | Cellular senescence | 71/2418 | 156/8465 | 4.17e-06 | 3.75e-05 | 2.42e-05 | 71 |
| hsa0520527 | Oral cavity | LP | Proteoglycans in cancer | 77/2418 | 205/8465 | 3.01e-03 | 1.29e-02 | 8.35e-03 | 77 |
| hsa0541537 | Oral cavity | LP | Diabetic cardiomyopathy | 106/2418 | 203/8465 | 6.51e-13 | 1.36e-11 | 8.74e-12 | 106 |
| hsa0301533 | Oral cavity | LP | mRNA surveillance pathway | 50/2418 | 97/8465 | 1.39e-06 | 1.50e-05 | 9.66e-06 | 50 |
| hsa0421837 | Oral cavity | LP | Cellular senescence | 71/2418 | 156/8465 | 4.17e-06 | 3.75e-05 | 2.42e-05 | 71 |
| hsa0520536 | Oral cavity | LP | Proteoglycans in cancer | 77/2418 | 205/8465 | 3.01e-03 | 1.29e-02 | 8.35e-03 | 77 |
| hsa0451043 | Oral cavity | NEOLP | Focal adhesion | 71/1112 | 203/8465 | 7.25e-16 | 7.68e-14 | 4.83e-14 | 71 |
| hsa0541562 | Oral cavity | NEOLP | Diabetic cardiomyopathy | 62/1112 | 203/8465 | 4.45e-11 | 1.57e-09 | 9.89e-10 | 62 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PPP1CC | SNV | Missense_Mutation | novel | c.452N>G | p.Thr151Ser | p.T151S | P36873 | protein_coding | deleterious_low_confidence(0.02) | benign(0.01) | TCGA-OL-A5RW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| PPP1CC | SNV | Missense_Mutation | novel | c.365G>A | p.Arg122Lys | p.R122K | P36873 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.967) | TCGA-UU-A93S-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| PPP1CC | SNV | Missense_Mutation | c.493N>A | p.Val165Met | p.V165M | P36873 | protein_coding | tolerated_low_confidence(0.07) | benign(0.332) | TCGA-DS-A0VK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD | |
| PPP1CC | SNV | Missense_Mutation | c.348N>T | p.Glu116Asp | p.E116D | P36873 | protein_coding | tolerated_low_confidence(0.17) | benign(0.003) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| PPP1CC | SNV | Missense_Mutation | novel | c.308C>T | p.Thr103Met | p.T103M | P36873 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.951) | TCGA-AZ-6598-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PPP1CC | SNV | Missense_Mutation | c.28G>A | p.Asp10Asn | p.D10N | P36873 | protein_coding | tolerated_low_confidence(0.07) | benign(0.078) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| PPP1CC | SNV | Missense_Mutation | c.902A>C | p.Lys301Thr | p.K301T | P36873 | protein_coding | deleterious_low_confidence(0.04) | possibly_damaging(0.662) | TCGA-QG-A5YV-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | xeloda | CR | |
| PPP1CC | SNV | Missense_Mutation | novel | c.610N>A | p.Leu204Ile | p.L204I | P36873 | protein_coding | deleterious_low_confidence(0.03) | benign(0.373) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| PPP1CC | SNV | Missense_Mutation | novel | c.941G>T | p.Arg314Met | p.R314M | P36873 | protein_coding | deleterious_low_confidence(0.02) | possibly_damaging(0.802) | TCGA-AJ-A2QO-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PPP1CC | SNV | Missense_Mutation | novel | c.268N>A | p.Leu90Ile | p.L90I | P36873 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.87) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |